World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
96
Citations
41132
World Ranking
9547
National Ranking
522

Jalid Sehouli publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Jalid Sehouli sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 1,212 publications — 97th percentile

97% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Jalid Sehouli D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Jalid Sehouli sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 96 D-Index — 53rd percentile

53% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Jalid Sehouli is affiliated with Charité - University Medicine Berlin in Germany. Their research primarily spans the field of Medicine, with significant contributions to subfields such as Reproductive Medicine, Oncology, Obstetrics and Gynecology, Surgery, and Pulmonary and Respiratory Medicine.

The scientist's work covers key topics including:

  • Ovarian cancer diagnosis and treatment
  • Endometrial and Cervical Cancer Treatments
  • PARP inhibition in cancer therapy
  • Cervical Cancer and HPV Research
  • BRCA gene mutations in cancer
  • Endometriosis Research and Treatment
  • Intraperitoneal and Appendiceal Malignancies

They have published extensively in various frequent venues, notably:

  • International Journal of Gynecological Cancer
  • Journal of Clinical Oncology
  • Geburtshilfe und Frauenheilkunde
  • Cancers
  • Archives of Gynecology and Obstetrics

Prominent recent papers authored or co-authored by Jalid Sehouli include:

  • ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma, 2020, International Journal of Gynecological Cancer
  • Atezolizumab, Bevacizumab, and Chemotherapy for Newly Diagnosed Stage III or IV Ovarian Cancer: Placebo-Controlled Randomized Phase III Trial (IMagyn050/GOG 3015/ENGOT-OV39), 2021, Journal of Clinical Oncology
  • Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): a randomised, double-blind, phase 3 clinical trial, 2024, The Lancet
  • Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1/ENGOT-ov25 trial, 2023, Annals of Oncology
  • Stable expansion of high-grade serous ovarian cancer organoids requires a low-Wnt environment, 2020, The EMBO Journal

Frequent co-authors collaborating with Sehouli include:

  • Elena Ioana Braicu
  • Philipp Harter
  • Ignace Vergote
  • Pauline Wimberger
  • Felix Hilpert

Best Publications

  • A phase 3 trial of bevacizumab in ovarian cancer.

    Timothy J Perren;Ann Marie Swart;Jacobus Pfisterer;Jonathan A Ledermann

  • Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer.

    Isabelle Ray-Coquard;Patricia Pautier;Sandro Pignata;David Pérol

  • ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma.

    Nicole Concin;Xavier Matias-Guiu;Ignace Vergote;David Cibula

  • ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease

    N. Colombo;C. Sessa;A. du Bois;J. Ledermann

  • Pegylated Liposomal Doxorubicin and Carboplatin Compared With Paclitaxel and Carboplatin for Patients With Platinum-Sensitive Ovarian Cancer in Late Relapse

    Eric Pujade-Lauraine;Uwe Wagner;Elisabeth Aavall-Lundqvist;Val Gebski

  • Surgery in Recurrent Ovarian Cancer: The Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR Trial

    Philipp Harter;Andreas du Bois;Maik Hahmann;Annette Hasenburg

  • A Randomized Trial of Lymphadenectomy in Patients with Advanced Ovarian Neoplasms

    Philipp Harter;Jalid Sehouli;Domenica Lorusso;Alexander Reuss

  • Mass spectrometry-based metabolic profiling reveals different metabolite patterns in invasive ovarian carcinomas and ovarian borderline tumors.

    Carsten Denkert;Jan Budczies;Tobias Kind;Wilko Weichert

  • The Notch and Wnt pathways regulate stemness and differentiation in human fallopian tube organoids.

    Mirjana Kessler;Karen Hoffmann;Volker Brinkmann;Oliver Thieck

  • Malignant ascites-derived exosomes of ovarian carcinoma patients contain CD24 and EpCAM.

    Steffen Runz;Sascha Keller;Christian Rupp;Alexander Stoeck;Alexander Stoeck

  • Systemic presence and tumor-growth promoting effect of ovarian carcinoma released exosomes

    Sascha Keller;Anne-Kathleen König;Frederik Marmé;Steffen Runz

  • Systematic review and meta-analysis of antibiotic therapy for bone and joint infections

    Dirk Stengel;Kai Bauwens;Jalid Sehouli;Axel Ekkernkamp

  • Magnetic nanoparticles for interstitial thermotherapy--feasibility, tolerance and achieved temperatures.

    Peter Wust;Uwe Gneveckow;Manfred Johannsen;Dirk Böhmer

  • Prospective Validation Study of a Predictive Score for Operability of Recurrent Ovarian Cancer: The Multicenter Intergroup Study DESKTOP II. A Project of the AGO Kommission OVAR, AGO Study Group, NOGGO, AGO-Austria, and MITO

    Philipp Harter;Jalid Sehouli;Alexander Reuss;Annette Hasenburg

  • The impact of second to sixth line therapy on survival of relapsed ovarian cancer after primary taxane/platinum-based therapy

    L. C. Hanker;S. Loibl;N. Burchardi;J. Pfisterer

  • Contemporary management of endometrial cancer

    Jason D Wright;Nicanor I Barrena Medel;Jalid Sehouli;Keiichi Fujiwara

  • Expression of the nuclear export protein chromosomal region maintenance/exportin 1/Xpo1 is a prognostic factor in human ovarian cancer.

    Aurelia Noske;Wilko Weichert;Silvia Niesporek;Annika Röske

  • Prognostic impact of programmed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor-infiltrating lymphocytes in ovarian high grade serous carcinoma.

    Silvia Darb-Esfahani;Catarina Alisa Kunze;Hagen Kulbe;Jalid Sehouli

  • ErbB-3 Predicts Survival in Ovarian Cancer

    Berno Tanner;Dirk Hasenclever;Katja Stern;Wiebke Schormann

  • Atezolizumab, Bevacizumab, and Chemotherapy for Newly Diagnosed Stage III or IV Ovarian Cancer: Placebo-Controlled Randomized Phase III Trial (IMagyn050/GOG 3015/ENGOT-OV39).

    Kathleen N Moore;Kathleen N Moore;Michael Bookman;Jalid Sehouli;Austin Miller

Frequent Co-Authors

Carsten Denkert
Carsten Denkert Philipp University of Marburg
Andreas du Bois
Andreas du Bois Johannes Gutenberg University of Mainz
Manfred Dietel
Manfred Dietel Charité - University Medicine Berlin
Peter Hillemanns
Peter Hillemanns Hannover Medical School
Christian Marth
Christian Marth Innsbruck Medical University
Giovanni Scambia
Giovanni Scambia Catholic University of the Sacred Heart
Wilko Weichert
Wilko Weichert Technical University of Munich
Nicoletta Colombo
Nicoletta Colombo University of Milano-Bicocca
Domenica Lorusso
Domenica Lorusso Catholic University of the Sacred Heart

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Interested in healthcare but not sure if a traditional medical degree is right for you? There are diverse online degree and certification options that can help you start your medical career. Many students consider entering nursing as a practical choice. For those looking to switch careers without a nursing background, the cheapest direct entry msn programs offer a fast and affordable route to advanced nursing roles.

If undergraduate nursing is your path, you may want to explore what is the easiest nursing school to get into to boost your chances of acceptance and reduce application stress.

Not all healthcare careers require direct patient care. Medical coding and billing are in high demand and can be pursued fully online. Check the medical billing and coding schools online for accredited programs that also offer financial aid.

For those seeking practical nursing pathways with fewer admission barriers, some schools offer an lpn program without teas test requirements, making it easier to get started in patient care roles.

Exploring these options can help you discover the right healthcare career to match your ambitions and personal circumstances.

Best Scientists Citing Jalid Sehouli

Trending Scientists

Recently Published Articles